Loading company
Revolution Medicines, Inc.
RVMD · Nasdaq · ·
Next earnings: November 4, 2026
$204.57+1.4%Sep 29 close
- 1M
- -1.6%
- 6M
- +120.7%
- 1Y
- +338.1%
- 5Y
- +586.9%
RVMD · Nasdaq · ·
Next earnings: November 4, 2026
$204.57+1.4%Sep 29 close
Revolution Medicines, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $742K | -100.00% |
| Profit | -$644.4M | -$247.8M | -160.05% |
| Profit per share | -$3.06 | -$1.31 | -133.59% |
| Free Cash Flow | -$389.6M | -$229.2M | -69.98% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“This has been a transformational period for Revolution Medicines, as we rapidly translated unprecedented Phase 3 results for daraxonrasib into an active Expanded Access Program and the filing of our first New Drug Application to the U.S. Food and Drug Administration on behalf of patients with previously treated metastatic pancreatic cancer,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. These product candidates are investigational and have not been approved for commercial use in any indication. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Revolution Medicines, Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Revolution Medicines, Inc. has no earnings call transcript available.